Paper
13 May 2015 The Ad5 [E1-, E2b-]-based vector: a new and versatile gene delivery platform
Frank R. Jones, Elizabeth S. Gabitzsch, Joseph P. Balint Jr.
Author Affiliations +
Abstract
Based upon advances in gene sequencing and construction, it is now possible to identify specific genes or sequences thereof for gene delivery applications. Recombinant adenovirus serotype-5 (Ad5) viral vectors have been utilized in the settings of gene therapy, vaccination, and immunotherapy but have encountered clinical challenges because they are recognized as foreign entities to the host. This recognition leads to an immunologic clearance of the vector that contains the inserted gene of interest and prevents effective immunization(s). We have reported on a new Ad5-based viral vector technology that can be utilized as an immunization modality to induce immune responses even in the presence of Ad5 vector immunity. We have reported successful immunization and immunotherapy results to infectious diseases and cancers. This improved recombinant viral platform (Ad5 [E1-, E2b-]) can now be utilized in the development of multiple vaccines and immunotherapies.
© (2015) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Frank R. Jones, Elizabeth S. Gabitzsch, and Joseph P. Balint Jr. "The Ad5 [E1-, E2b-]-based vector: a new and versatile gene delivery platform", Proc. SPIE 9490, Advances in Global Health through Sensing Technologies 2015, 94900L (13 May 2015); https://doi.org/10.1117/12.2183244
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Cancer

Tumor growth modeling

Animal model studies

Colorectal cancer

Proteins

Clinical trials

Back to Top